The 2nd Edition of the Retinal Atlas Has Been Published
The Retinal Atlas is now the most widely distributed textbook in the field of ophthalmology, the recipient of the Prose Award for medical text, relevant enough to be translated into 7 languages. It is now in its sixth year, and a 2nd edition called The Retinal Atlas has been published, with Dr. K. Bailey Freund […]
Pathologic Myopia Textbook Authored By Macula Foundation Supporters
Severe myopia referred to as pathologic myopia was the subject of a textbook authored and edited by Macula Foundation supporters. This disease of the retina and macula is a major cause of severe vision worldwide, particularly people of Asiatic background. It results in detachment of the retina, dry and wet forms of macular degeneration, macular […]
OCT Angiography Research Supported By The Macula Foundation
The Macula Foundation is supporting OCT Angiography research for four companies which manufacture a device which can determine flow of the retinal and choroidal circulations without the use of a contrast dye. The risk of intravenous dye injection is eliminated and these circulations and their abnormalities can be imaged with high discrimination and resolution. […]
Discovery of Pachychoroid Disease
Our understanding of “pachychoroid disease” has expanded greatly thanks to multimodal clinical imaging technologies. Cross-sectional and en face depth-resolved imaging, such as enhanced depth imaging (EDI) OCT, Swept-Source OCT (SS-OCT), and OCT angiography (OCTa), have enabled a deeper appreciation for the role of the choroid in a wide-range of macular disorders. Pachychoroid disease is a […]
Anti-VEGF Medication Discovery Supported by The Macula Foundation
The Macula Foundation supported research in the late 1990s, leading to the discovery of Anti-VEGF drugs to be injected into the eye for treatment of “wet” macular degeneration. The investigator at that time was Dr. David Guyer who discovered MACUGEN, which was the first approved drug for this purpose. The scientific advisor of this company […]